Get the Stockscreener App
5.05
2.02%
0.10
After Hours:
5.13
0.08
+1.58%
Aquestive Therapeutics Inc stock is traded at $5.05, with a volume of 2.67M.
It is up +2.02% in the last 24 hours and up +33.60% over the past month.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
See More
Previous Close:
$4.95
Open:
$5.04
24h Volume:
2.67M
Relative Volume:
1.65
Market Cap:
$503.60M
Revenue:
$58.36M
Net Income/Loss:
$-25.72M
P/E Ratio:
-13.87
EPS:
-0.3641
Net Cash Flow:
$-24.91M
1W Performance:
-6.83%
1M Performance:
+33.60%
6M Performance:
+71.77%
1Y Performance:
+10.99%
1-Day Range:
$5.02
$5.2699
1-Week Range:
$4.75
$5.60
52-Week Range:
$2.12
$5.80
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Name
Aquestive Therapeutics Inc
Sector
Phone
908-941-1900
Address
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
5.05 | 590.35M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
148.20 | 66.22B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.93 | 22.45B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
405.02 | 17.93B | 2.99B | 1.21B | 1.13B | 25.06 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-10-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Apr-22-19 | Initiated | H.C. Wainwright | Buy |
| Jan-03-19 | Initiated | Lake Street | Buy |
| Aug-20-18 | Initiated | JMP Securities | Mkt Outperform |
| Aug-20-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Aquestive Therapeutics Inc Stock (AQST) Latest News
Oppenheimer Issues Positive Forecast for Aquestive Therapeutics (NASDAQ:AQST) Stock Price - MarketBeat
Aquestive Bets Big On Oral Epinephrine’s Market Debut - Finimize
Insider Selling: Aquestive Therapeutics (NASDAQ:AQST) Insider Sells 15,000 Shares of Stock - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Trading Down 6.4% Following Insider Selling - MarketBeat
Aquestive Therapeutics, Inc. $AQST Shares Purchased by Everstar Asset Management LLC - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Stock Rating Upgraded by Lifesci Capital - MarketBeat
AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA - MSN
Aquestive Therapeutics SVP sells $79,500 in shares By Investing.com - Investing.com Australia
Aquestive therapeutics (AQST) COO Jung Cassie sells $310,900 in shares By Investing.com - Investing.com Australia
Aquestive Therapeutics SVP sells $79,500 in shares - Investing.com
Aquestive therapeutics (AQST) COO Jung Cassie sells $310,900 in shares - Investing.com
Aquestive Therapeutics at H.C. Wainwright: Anaphylm™ Poised for Growth By Investing.com - Investing.com Canada
Multi Factor Analysis Ranks Aquestive Therapeutics Inc. as Strong BuyMarket Activity Report & Community Consensus Picks - beatles.ru
Aquestive Therapeutics Highlights at Global Investor Conference - TipRanks
Aquestive Therapeutics says FDA AdCom not needed for review of Anaphylm - The Pharma Letter
Measuring Aquestive Therapeutics Inc.’s beta against major indicesEarnings Summary Report & Capital Efficient Trading Techniques - Newser
Aquestive Therapeutics Inc. stock retracement – recovery analysisJuly 2025 Fed Impact & AI Powered Market Entry Strategies - Newser
Aquestive Therapeutics: Expect Its Torrid Pace To Relax (Rating Downgrade) (NASDAQ:AQST) - Seeking Alpha
Is Aquestive Therapeutics Inc. stock good for income investorsJuly 2025 Volume & AI Enhanced Trading Alerts - خودرو بانک
What are Aquestive Therapeutics Inc.’s recent SEC filings showingEarnings Growth Summary & Long-Term Capital Growth Strategies - خودرو بانک
Is Aquestive Therapeutics Inc. stock a smart retirement pickWeekly Investment Summary & Capital Protection Trading Alerts - خودرو بانک
Can Aquestive Therapeutics Inc. grow without external fundingJuly 2025 Breakouts & AI Powered Buy/Sell Recommendations - خودرو بانک
Aquestive jumps as FDA says no AdCom for allergy therapy Anaphylm - MSN
Aquestive Therapeutics' Strategic Path to Anaphylm Approval and Market Capture - AInvest
Aquestive Therapeutics: No AdCom For Anaphylm Derisks January Approval Catalyst (AQST) - Seeking Alpha
Should you wait for a breakout in Aquestive Therapeutics Inc.Weekly Stock Analysis & Smart Investment Allocation Insights - Newser
News impact scoring models applied to Aquestive Therapeutics Inc.Share Buyback & Verified Entry Point Detection - Newser
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable - simplywall.st
Aquestive Therapeutics shares rise 2.17% premarket after FDA waives advisory committee meeting for Anaphylm. - AInvest
What Fibonacci levels say about Aquestive Therapeutics Inc. reboundTrade Analysis Report & Community Consensus Trade Signals - Newser
FDA won’t require advisory committee meeting for Aquestive’s anaphylaxis film - Investing.com Canada
Aquestive gains as allergy therapy undergoes FDA review - MSN
Evaluating Aquestive Therapeutics Inc. with trendline analysis2025 Market Trends & Low Drawdown Investment Ideas - Newser
Why Is Aquestive Therapeutics Stock Soaring Thursday?Aquestive Therapeutics (NASDAQ:AQST) - Benzinga
Aquestive Therapeutics Shares Rise, FDA Forgos Meeting on Anaphylm - MarketScreener
Aquestive Therapeutics at Cantor Global Healthcare Conference: Strategic Moves for ANNAFILM - Investing.com Canada
Aquestive Therapeutics shares surge 21.39% intraday after FDA waives advisory committee meeting for Anaphylm, a device-free, sublingual epinephrine film for severe allergic reactions. - AInvest
Analyzing recovery setups for Aquestive Therapeutics Inc. investorsJuly 2025 WrapUp & Verified Chart Pattern Trade Signals - Newser
Aquestive Therapeutics, Inc. Announces FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm?? - MarketScreener
Aquestive Therapeutics Shares Soar 20% on FDA Approval Pathway - AInvest
Aquestive says no FDA AdCom for Anaphylm (AQST:NASDAQ) - Seeking Alpha
Aquestive climbs after US FDA says no advisory panel needed for epinephrine film - TradingView
Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™ - The Manila Times
Aquestive Therapeutics Announces that FDA Will Not Require - GlobeNewswire
First-Ever Needle-Free Epinephrine Film: Aquestive's Anaphylm Clears Key FDA Hurdle Without Committee Review - Stock Titan
Will Aquestive Therapeutics Inc. stock recover after recent dropMarket Growth Summary & Risk Managed Trade Strategies - Newser
How moving averages guide Aquestive Therapeutics Inc. tradingJuly 2025 Institutional & Stepwise Swing Trade Plans - Newser
Published on: 2025-09-03 22:42:37 - Newser
Can Aquestive Therapeutics Inc. ride the EV waveSell Signal & Intraday High Probability Alerts - خودرو بانک
What momentum shifts mean for Aquestive Therapeutics Inc.Weekly Trend Summary & Safe Capital Growth Plans - Newser
Risk adjusted return profile for Aquestive Therapeutics Inc. analyzed2025 Breakouts & Breakdowns & Safe Capital Allocation Plans - Newser
Aquestive Therapeutics Inc Stock (AQST) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):